GPT and steatosis: Similar findings were reported in the meta-analysis by Musa-Veloso et al. [287], which demonstrated that omega-3 PUFAs (EPA: minimum daily dose: 178 mg; maximum: 4626 mg; DHA: minimum daily dose: 200 mg; maximum 2520 mg) were useful in the dietary management of patients with NAFLD: omega-3 PUFA supplementation improved 6 of 13 metabolic outcomes included (TC, LDL, HDL, TG, HOMA-IR, and BMI) as well as ALT and GGT (but not AST), liver lipid content (assessed by MRI), and steatosis.